LENZ Partners with Everest for VIZZ Development in Greater China
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 08 2026
0mins
Source: NASDAQ.COM
- Agreement Signed: LENZ Therapeutics has partnered with Everest Medicines to grant rights for the development, manufacturing, and commercialization of VIZZ eye drops in Greater China, marking a strategic expansion for LENZ in the ophthalmology market.
- Significant Market Potential: VIZZ is the first aceclidine-based eye drop approved in the U.S. for treating presbyopia, addressing the growing patient demand and potentially generating up to $85 million in regulatory sales milestones for LENZ.
- Future Outlook: LENZ submitted a New Drug Application for LNZ100 to the NMPA in September 2025, with approval expected in Q1 2027, further enhancing its competitive position in the Chinese market.
- Stock Performance: LENZ shares have traded between $6.61 and $50.40 over the past year, closing at $7.01, down 2.64%, but showing a slight recovery to $7.08 in overnight trading, indicating market interest in its future developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LENZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LENZ
Wall Street analysts forecast LENZ stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.600
Low
52.00
Averages
57.50
High
62.00
Current: 5.600
Low
52.00
Averages
57.50
High
62.00
About LENZ
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LENZ Launches Telehealth Platform for VIZZ
- Telehealth Platform Launch: LENZ Therapeutics has introduced a telehealth platform for VIZZ, enabling online evaluations by independent eye care professionals, which is expected to significantly enhance accessibility for the 128 million Americans suffering from presbyopia and improve user experience.
- Advertising Campaign Support: The nationwide TV advertising campaign featuring brand spokesperson Sarah Jessica Parker aims to boost consumer awareness of VIZZ, which is anticipated to accelerate market penetration and user adoption of the product.
- Convenient Prescription Fulfillment: By partnering with an e-pharmacy, prescriptions for VIZZ will be automatically processed and delivered to patients' homes, streamlining the entire journey from consultation to medication, thereby enhancing consumer convenience and satisfaction.
- Significant Market Potential: As the first FDA-approved aceclidine eye drop, VIZZ targets the 1.8 billion people globally affected by presbyopia, positioning LENZ to meet the growing market demand and strengthen its leadership in the ophthalmic pharmaceutical sector.
See More
LENZ and Arrotex Sign Exclusive License Agreement for VIZZ in Australia and New Zealand
- Exclusive License Agreement: LENZ Therapeutics has signed an exclusive license agreement with Arrotex Pharmaceuticals, allowing Arrotex to register and commercialize VIZZ™ in Australia and New Zealand, marking a significant expansion in LENZ's global commercial partnership network and expected to enhance VIZZ's market reach.
- Significant Market Potential: VIZZ is the first FDA-approved aceclidine eye drop for treating presbyopia, targeting approximately 1.8 billion people globally and 128 million in the U.S., which is anticipated to meet the growing market demand and drive revenue growth for LENZ.
- Commercialization Advantages: As Australia's largest pharmaceutical company, Arrotex possesses an extensive pharmacy partnership network and a proven track record of launching innovative medicines, which will accelerate VIZZ's market penetration and improve patient access and quality of life.
- Strategic Collaboration Outlook: This partnership not only provides LENZ with upfront payments and significant profit sharing but also enhances VIZZ's brand recognition in the Asia-Pacific region through Arrotex's market influence, further solidifying LENZ's leadership position in the global presbyopia treatment market.
See More
Biotech Sector Sees Surge in FDA and Global Approvals
- FDA Approval Boosts Innovation: Guardant Health (GH) secured FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS, highlighting the growing importance of liquid biopsy in advanced cancer treatment, which is expected to drive GH's market share growth.
- Therapy Expansion: Eli Lilly (LLY) received FDA approval for an every-eight-week maintenance dose of EBGLYSS, with Q1 2026 sales surging 141% to $145 million, reflecting strong demand in its immunology portfolio and further solidifying the company's market position.
- China Market Breakthrough: Vor Bio (VOR) announced that Telitacicept received approval from China's NMPA, becoming the only approved therapy for Sjögren's disease in the country, supported by positive Phase 3 trial data, which is expected to significantly improve patient quality of life and expand market reach.
- EU Approval for New Therapy: Sanofi (SNY) secured European Commission approval for Sarclisa in newly diagnosed multiple myeloma patients, based on Phase 3 IRAKLIA trial results, which is expected to enhance Sarclisa's application range and strengthen the company's competitiveness in blood cancer treatment.
See More
LENZ Partners with Everest for VIZZ Development in Greater China
- Agreement Signed: LENZ Therapeutics has partnered with Everest Medicines to grant rights for the development, manufacturing, and commercialization of VIZZ eye drops in Greater China, marking a strategic expansion for LENZ in the ophthalmology market.
- Significant Market Potential: VIZZ is the first aceclidine-based eye drop approved in the U.S. for treating presbyopia, addressing the growing patient demand and potentially generating up to $85 million in regulatory sales milestones for LENZ.
- Future Outlook: LENZ submitted a New Drug Application for LNZ100 to the NMPA in September 2025, with approval expected in Q1 2027, further enhancing its competitive position in the Chinese market.
- Stock Performance: LENZ shares have traded between $6.61 and $50.40 over the past year, closing at $7.01, down 2.64%, but showing a slight recovery to $7.08 in overnight trading, indicating market interest in its future developments.
See More
LENZ and Everest Medicines Sign Asset Purchase Agreement for VIZZ® in Greater China
- Asset Purchase Agreement: LENZ Therapeutics announced a definitive asset purchase agreement with Everest Medicines to acquire the development, manufacturing, and commercialization rights for VIZZ® in Greater China, which signifies a strategic expansion into the ophthalmic market.
- Unique FDA-Approved Product: VIZZ® is the first and only FDA-approved aceclidine-based eye drop engineered to treat presbyopia, addressing the growing demand for vision improvement among the aging population, thus presenting significant market potential.
- Regulatory Submission Timeline: The New Drug Application for VIZZ® was submitted in China in September 2025, with regulatory approval anticipated in the first quarter of 2027, establishing a timeline that supports future revenue growth for the company.
- Financial Upside Potential: Under the transaction terms, Everest Medicines will assume all rights and obligations from the original license agreement between LENZ and Corxel, allowing LENZ to receive up to $85 million in remaining regulatory and sales milestone payments, along with tiered mid-single-digit to low double-digit royalties on future net sales, highlighting its ongoing financial upside potential.
See More
LENZ and Everest Enter Asset Purchase Agreement for VIZZ in Greater China
- Asset Purchase Agreement: LENZ Therapeutics has signed an asset purchase agreement with Everest Medicines, granting Everest the rights to develop, manufacture, and commercialize VIZZ (LNZ100) in Greater China, significantly enhancing LENZ's market penetration in the region.
- Regulatory Milestone Revenue: LENZ stands to receive up to $85 million in regulatory and sales milestone payments from this transaction, along with tiered mid-single-digit to low double-digit royalties on net sales in Greater China, further strengthening the company's financial stability.
- Market Demand Opportunity: As the population of presbyopia patients continues to grow, LNZ100 offers a non-invasive treatment option that addresses the urgent market need for innovative ophthalmic therapies, expected to drive the company's strategic development in the ophthalmology sector.
- Collaborative Outlook: The partnership between LENZ and Everest will accelerate the regulatory approval and commercialization of LNZ100 in China, anticipated to provide a transformative treatment option for millions of presbyopia patients, thereby solidifying LENZ's competitive position in the global market.
See More
LENZ Launches Telehealth Platform for VIZZ
- Telehealth Platform Launch: LENZ Therapeutics has introduced a telehealth platform for VIZZ, enabling online evaluations by independent eye care professionals, which is expected to significantly enhance accessibility for the 128 million Americans suffering from presbyopia and improve user experience.
- Advertising Campaign Support: The nationwide TV advertising campaign featuring brand spokesperson Sarah Jessica Parker aims to boost consumer awareness of VIZZ, which is anticipated to accelerate market penetration and user adoption of the product.
- Convenient Prescription Fulfillment: By partnering with an e-pharmacy, prescriptions for VIZZ will be automatically processed and delivered to patients' homes, streamlining the entire journey from consultation to medication, thereby enhancing consumer convenience and satisfaction.
- Significant Market Potential: As the first FDA-approved aceclidine eye drop, VIZZ targets the 1.8 billion people globally affected by presbyopia, positioning LENZ to meet the growing market demand and strengthen its leadership in the ophthalmic pharmaceutical sector.
See More
LENZ and Arrotex Sign Exclusive License Agreement for VIZZ in Australia and New Zealand
- Exclusive License Agreement: LENZ Therapeutics has signed an exclusive license agreement with Arrotex Pharmaceuticals, allowing Arrotex to register and commercialize VIZZ™ in Australia and New Zealand, marking a significant expansion in LENZ's global commercial partnership network and expected to enhance VIZZ's market reach.
- Significant Market Potential: VIZZ is the first FDA-approved aceclidine eye drop for treating presbyopia, targeting approximately 1.8 billion people globally and 128 million in the U.S., which is anticipated to meet the growing market demand and drive revenue growth for LENZ.
- Commercialization Advantages: As Australia's largest pharmaceutical company, Arrotex possesses an extensive pharmacy partnership network and a proven track record of launching innovative medicines, which will accelerate VIZZ's market penetration and improve patient access and quality of life.
- Strategic Collaboration Outlook: This partnership not only provides LENZ with upfront payments and significant profit sharing but also enhances VIZZ's brand recognition in the Asia-Pacific region through Arrotex's market influence, further solidifying LENZ's leadership position in the global presbyopia treatment market.
See More
Biotech Sector Sees Surge in FDA and Global Approvals
- FDA Approval Boosts Innovation: Guardant Health (GH) secured FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS, highlighting the growing importance of liquid biopsy in advanced cancer treatment, which is expected to drive GH's market share growth.
- Therapy Expansion: Eli Lilly (LLY) received FDA approval for an every-eight-week maintenance dose of EBGLYSS, with Q1 2026 sales surging 141% to $145 million, reflecting strong demand in its immunology portfolio and further solidifying the company's market position.
- China Market Breakthrough: Vor Bio (VOR) announced that Telitacicept received approval from China's NMPA, becoming the only approved therapy for Sjögren's disease in the country, supported by positive Phase 3 trial data, which is expected to significantly improve patient quality of life and expand market reach.
- EU Approval for New Therapy: Sanofi (SNY) secured European Commission approval for Sarclisa in newly diagnosed multiple myeloma patients, based on Phase 3 IRAKLIA trial results, which is expected to enhance Sarclisa's application range and strengthen the company's competitiveness in blood cancer treatment.
See More
LENZ Partners with Everest for VIZZ Development in Greater China
- Agreement Signed: LENZ Therapeutics has partnered with Everest Medicines to grant rights for the development, manufacturing, and commercialization of VIZZ eye drops in Greater China, marking a strategic expansion for LENZ in the ophthalmology market.
- Significant Market Potential: VIZZ is the first aceclidine-based eye drop approved in the U.S. for treating presbyopia, addressing the growing patient demand and potentially generating up to $85 million in regulatory sales milestones for LENZ.
- Future Outlook: LENZ submitted a New Drug Application for LNZ100 to the NMPA in September 2025, with approval expected in Q1 2027, further enhancing its competitive position in the Chinese market.
- Stock Performance: LENZ shares have traded between $6.61 and $50.40 over the past year, closing at $7.01, down 2.64%, but showing a slight recovery to $7.08 in overnight trading, indicating market interest in its future developments.
See More
LENZ and Everest Medicines Sign Asset Purchase Agreement for VIZZ® in Greater China
- Asset Purchase Agreement: LENZ Therapeutics announced a definitive asset purchase agreement with Everest Medicines to acquire the development, manufacturing, and commercialization rights for VIZZ® in Greater China, which signifies a strategic expansion into the ophthalmic market.
- Unique FDA-Approved Product: VIZZ® is the first and only FDA-approved aceclidine-based eye drop engineered to treat presbyopia, addressing the growing demand for vision improvement among the aging population, thus presenting significant market potential.
- Regulatory Submission Timeline: The New Drug Application for VIZZ® was submitted in China in September 2025, with regulatory approval anticipated in the first quarter of 2027, establishing a timeline that supports future revenue growth for the company.
- Financial Upside Potential: Under the transaction terms, Everest Medicines will assume all rights and obligations from the original license agreement between LENZ and Corxel, allowing LENZ to receive up to $85 million in remaining regulatory and sales milestone payments, along with tiered mid-single-digit to low double-digit royalties on future net sales, highlighting its ongoing financial upside potential.
See More
LENZ and Everest Enter Asset Purchase Agreement for VIZZ in Greater China
- Asset Purchase Agreement: LENZ Therapeutics has signed an asset purchase agreement with Everest Medicines, granting Everest the rights to develop, manufacture, and commercialize VIZZ (LNZ100) in Greater China, significantly enhancing LENZ's market penetration in the region.
- Regulatory Milestone Revenue: LENZ stands to receive up to $85 million in regulatory and sales milestone payments from this transaction, along with tiered mid-single-digit to low double-digit royalties on net sales in Greater China, further strengthening the company's financial stability.
- Market Demand Opportunity: As the population of presbyopia patients continues to grow, LNZ100 offers a non-invasive treatment option that addresses the urgent market need for innovative ophthalmic therapies, expected to drive the company's strategic development in the ophthalmology sector.
- Collaborative Outlook: The partnership between LENZ and Everest will accelerate the regulatory approval and commercialization of LNZ100 in China, anticipated to provide a transformative treatment option for millions of presbyopia patients, thereby solidifying LENZ's competitive position in the global market.
See More
